| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/20000 | Human,Mouse,Rat |
| Aliases | CDKN3; CDI1; CIP2; KAP; Cyclin-dependent kinase inhibitor 3; CDK2-associated dual-specificity phosphatase; Cyclin-dependent kinase interactor 1; Cyclin-dependent kinase-interacting protein 2; Kinase-associated phosphatase |
| Entrez GeneID | 1033; |
| WB Predicted band size | 23kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from the Internal region of human CDKN3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于CDKN3抗体的3篇参考文献示例(注：文献信息为模拟概括，实际引用需核实原文)：
1. **文献名称**：*CDKN3 Expression in Hepatocellular Carcinoma: A Prognostic Marker via p53 Pathway Regulation*
**作者**：Li et al.
**摘要**：该研究通过免疫组织化学(IHC)使用CDKN3抗体，发现CDKN3在肝癌组织中高表达，且与患者不良预后相关。实验表明CDKN3通过抑制p53通路促进肿瘤进展。
2. **文献名称**：*Role of CDKN3 in Breast Cancer Cell Proliferation Assessed by shRNA and Antibody-based Knockdown*
**作者**：Smith et al.
**摘要**：作者利用CDKN3特异性抗体进行Western blot和流式细胞术，验证了CDKN3在乳腺癌细胞中的功能。结果显示抑制CDKN3可降低细胞周期蛋白依赖性激酶活性，减缓肿瘤生长。
3. **文献名称**：*CDKN3 as a Novel Therapeutic Target in Gastric Cancer: Validation by Immunohistochemical Staining*
**作者**：Wang et al.
**摘要**：研究通过CDKN3抗体进行组织芯片分析，证实CDKN3在胃癌中异常高表达，并与化疗耐药性相关。体外实验进一步表明靶向CDKN3可增强化疗药物敏感性。
(如需具体文献，建议通过PubMed或Web of Science以“CDKN3 antibody”为关键词检索最新研究。)
The CDKN3 (Cyclin-Dependent Kinase Inhibitor 3) gene encodes a protein that belongs to the dual-specificity phosphatase family, playing a critical role in cell cycle regulation. CDKN3. also known as KAP (CDK2-Associated Phosphatase), primarily functions by dephosphorylating and inactivating CDK2. a cyclin-dependent kinase essential for G1/S phase transition. This activity positions CDKN3 as a negative regulator of cell cycle progression, although its role in cancer remains complex. Studies suggest CDKN3 may act as a tumor suppressor in some contexts, while overexpression or dysregulation has been linked to oncogenic effects in certain cancers, highlighting its context-dependent functionality.
CDKN3 antibodies are vital tools for investigating its expression patterns, subcellular localization, and interactions in both physiological and pathological conditions. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to assess CDKN3 levels in tissue samples or cell lines. In cancer research, CDKN3 antibodies help elucidate its dual role in tumorigenesis, with elevated expression observed in malignancies like hepatocellular carcinoma, glioblastoma, and breast cancer, often correlating with poor prognosis. Additionally, they aid in studying CDKN3's involvement in therapeutic resistance and potential as a biomarker or therapeutic target.
Commercial CDKN3 antibodies are typically developed against specific epitopes, with validation including knock-down/knockout controls to ensure specificity. Researchers must select antibodies validated for their intended applications, as variability in isoform detection or cross-reactivity can impact data interpretation. Ongoing studies continue to explore CDKN3's regulatory networks and clinical relevance, underscoring the importance of reliable antibody reagents in advancing our understanding of cell cycle dynamics and cancer biology.
×
